Oral Biol Res.  2022 Dec;46(4):150-157. 10.21851/obr.46.04.202212.150.

Case series of maxillary anterior bone augmentation with a novel biphasic calcium phosphate: a clinical and radiographic pilot study

• Lee JH
• Jung EH
• An HW
• Im JS
• Lee DW
• Yun JH

• KMID: 2537676
• DOI: http://doi.org/10.21851/obr.46.04.202212.150

Abstract

The purpose of this pilot case series was to evaluate the clinical and radiographic outcomes of employing newly developed alloplastic biphasic calcium phosphate (BCP) in guided bone regeneration (GBR) for maxillary anterior peri-implant defects. Six peri-implant dehiscence defects were grafted with BCP. For all included treatment sites, clinical (defect width [DW] and defect height [DH]), radiographic (horizontal hard tissue thickness [HT]), patient discomfort, and early wound healing outcomes were evaluated. At reentry surgery, all surgical sites indicated a change in DW, DH, HT0, HT1, HT2, and HT3 from 4.08±1.39 mm to 1.13±1.76 mm, 3.57±1.42 mm to 0.58±1.09 mm, 2.18±0.66 mm to 1.50±0.53 mm, 2.11±0.57 mm to 1.73±0.28 mm, 2.22±0.54 mm to 1.75±0.26 mm, and 2.63±0.87 mm to 1.83±0.46 mm, respectively. Significant differences were discovered between paired DW and DH (p<0.05), whereas radiographic parameters had no significant differences. The severity of pain and swelling was 4.8±1.9 and 6.5±1.9, respectively, and the duration of pain and swelling was 4.5±3.8 and 5.8±2.9 days, respectively, according to early postoperative discomfort assessment. No adverse reactions occurred at any treatment site. In terms of clinical and radiographic outcomes, the newly developed BCP is acceptable biocompatible and suitable for the GBR of maxillary anterior peri-implant dehiscence defects within the limitations of this study.

Keyword

Allografts; Bone regeneration; Bone substitutes; Dental implants